Moderna
Prix: 49.91Entreprise et modèle économique
Moderna is a biotechnology company focused on developing messenger RNA (mRNA) therapeutics and vaccines. Its core products include the COVID-19 vaccine and various candidates for infectious diseases, cancer, and rare diseases. The company primarily generates revenue from vaccine sales, with a significant portion derived from government contracts and partnerships. Moderna's business segments include research and development, manufacturing, and commercialization of its mRNA-based products.
Profil d’investissement
The investment profile of Moderna is more aligned with growth investors, given its focus on innovative mRNA technology and potential future product pipeline. However, the high risk associated with its current financial performance and market volatility may deter conservative investors. The stock may appeal to those with a medium to long-term horizon who are willing to navigate potential fluctuations.
Métriques fondamentales (expérimental)
- BPA (TTM) — bénéfice par action des 12 derniers mois, $
- -8.15 Risque
- Chiffre d’affaires QoQ — croissance trimestrielle du chiffre d’affaires
- -42.6% ↓
- Surprise BPA
- 60.9% meilleur que prévu
- Volatilité 20 j
- 3.9% stable
Suivre dans le portefeuille
Graphique des prix
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-06-11 05:23 | Conserver | Vendre | scenario_deterioration |
| 2026-06-05 02:43 | Vendre | Conserver | Weak fundamentals offset by recent price momentum. |
| 2026-06-03 02:47 | Conserver | Vendre | scenario_deterioration |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-05-04 13:36 | UBS | Objectif relevé | 36 → 45 | 47.465 |
| 2026-05-04 12:36 | RBC Capital | Objectif relevé | 35 → 38 | 46.87 |
| 2026-05-01 23:40 | Goldman Sachs | Objectif relevé | 43 → 49 | 45.37 |
Rien pour le moment